





Characterization of VLP

Yield & Capacity: ~5 doses/ml,~500 million doses/year (two production line at 1200L scale)

Structural analytical methods

Intact Molecular weight : LC-MS Amino acid sequence coverage: LC-MS/MS N-Terminal sequence: LC-MS/MS Peptide map: LC-MS/MS Particle size and distribution: DLS Secondary structure: Circular dichroism Particle morphology: TEM
 Type1
 Type2

 DLD

 Note:

 Note:

</tabult>

</tabult>

 Note:<

3D structures of all three VLPs similar to the viruses with a diameter of about 30 nm

WildType VLP







Confidential



Immunogenicity outcomes



GMT of neutralizing antibodies

GMT of Nab against Sabin poliovirus (PV) type 1, 2 and 3 on Day 1 pre-immunization and Day 29 post-immunization

Sero-protection rate (% of antibody titer > 1:8) of IPOL and VLP-Polio (Dose A/M/H) pre- and post-vaccination.

The VLP-Polio vaccine candidates were all highly immunogenic.





Seroprotection rate



Call for Collaboration

•VLP Based Penta and Hexa combo Vaccine co-development

•VLP based Time controlled releasing Polio Vaccine, Oral Pill Vaccine, MAP based Vaccine, VLP Polio mucosal vaccine.

Chunlin Xin

chunlin.xin@cansinotech.com Cell: +86-18521384406 WeChat: cwoodnc WhatsApp:+16173478976